A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer
- 247 Downloads
Breast cancer is the most common malignancy and the second leading cause of female cancer mortality in the United States. There is an urgent need for development of novel therapeutic approaches. In this study, we investigated the antitumor potential of a novel viral agent, an attenuated strain of measles virus deriving from the Edmonston vaccine lineage, genetically engineered to produce carcinoembryonic antigen (CEA) against breast cancer. CEA production as the virus replicates can serve as a marker of viral gene expression. Infection of a variety of breast cancer cell lines including MDA-MB-231, MCF7 and SkBr3 at different multiplicities of infection (MOIs) from 0.1 to 10 resulted in significant cytopathic effect consisting of extensive syncytia formation and massive cell death at 72–96 h from infection. All breast cancer lines overexpressed the measles virus receptor CD46 and supported robust viral replication, which correlated with CEA production. TUNEL assays indicated an apoptotic mechanism of syncytial death. The efficacy of this approach in vivo was examined in a subcutaneous Balb C/nude mouse model of MDA-MB-231 cells. Intravenous administration of MV-CEA at a total dose of 1.2×107 TCID50 resulted in statistically significant tumor growth delay ( p=0.005) and prolongation of survival ( p=0.001). In summary, MV-CEA has potent antitumor activity against breast cancer lines and xenografts. Monitoring marker peptide levels in the serum could serve as a low-risk method of detecting viral gene expression during treatment and could allow dose optimization and individualization of treatment. Trackable measles virus derivatives merit further exploration in breast cancer treatment.
Keywordsbreast cancer CEA measles virus MV-CEA virotherapy
Unable to display preview. Download preview PDF.
Supported by a Prospect Creek Foundation Grant. Also supported in part by an Eagles’ Grant (EG) and by Breast SPORE P50CA 116201-1 (JNI, EG).
- 14.Dingli D, Peng KW, Harvey ME, Greipp PR, O’Connor MK, Cattaneo R, Morris JC, Russell SJ: Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103(5): 1641–1646, 2004. Epub 2003 Nov 1646. Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | DisclaimerGoogle Scholar
- 17.Spearman C The method of right and wrong cases without Gauss’s formula Br J Psychol 1908, 2: 227–242Google Scholar
- 20.Rencher AC (2002) Methods of Multivariate Analysis 2 edn. John Wiley & Sons, New York, NYGoogle Scholar
- 21.Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme Cancer Res 2003, 63(10): 2462–2469PubMedGoogle Scholar
- 22.Dummer R, Bergh J, Karlsson Y, Horowitz JA, Mulder NH, Huinink DTB, Burg G, Hofbauer G, Osanto S Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors Cancer Gene Ther 2000, 7(7): 1069–1076PubMedCrossRefGoogle Scholar
- 25.Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial J Clin Oncol 2001, 19(14): 3422–3433PubMedGoogle Scholar
- 27.Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ: Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23(2): 209–214, 2005. Epub 2005 Jan 2030Google Scholar
- 28.Rushmere NK, Knowlden JM, Gee JM: Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 108(6): 930–936, 2004. Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | DisclaimerGoogle Scholar